Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 2Triple Negative Breast Neoplasms 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neoplasms 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Letrozole 221Capecitabine 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 132Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × decitabine and cedazuridine drug combination × Clear all
NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Indiana University

Phase 1 Completed
34 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡